202 related articles for article (PubMed ID: 34496925)
1. HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.
Bièche I; Coussy F; El-Botty R; Vacher S; Château-Joubert S; Dahmani A; Montaudon E; Reyes C; Gentien D; Reyal F; Ricci F; Nicolas A; Marchio C; Vincent-Salomon A; Laé M; Marangoni E
J Hematol Oncol; 2021 Sep; 14(1):143. PubMed ID: 34496925
[TBL] [Abstract][Full Text] [Related]
2. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Pareja F; Toss MS; Geyer FC; da Silva EM; Vahdatinia M; Sebastiao APM; Selenica P; Szatrowski A; Edelweiss M; Wen HY; Mihai R; Varga Z; Foschini MP; Rubin BP; Ellis IO; Chandarlapaty S; Jungbluth AA; Brogi E; Weigelt B; Reis-Filho JS; Rakha EA
Histopathology; 2020 May; 76(6):865-874. PubMed ID: 31887226
[TBL] [Abstract][Full Text] [Related]
4. Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity.
Ginter PS; McIntire PJ; Kurtis B; Mirabelli S; Motanagh S; Hoda S; Elemento O; Shin SJ; Mosquera JM
Mod Pathol; 2020 Sep; 33(9):1764-1772. PubMed ID: 32355271
[TBL] [Abstract][Full Text] [Related]
5. Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.
Baum JE; Sung KJ; Tran H; Song W; Ginter PS
Int J Surg Pathol; 2019 Jun; 27(4):441-445. PubMed ID: 30585117
[TBL] [Abstract][Full Text] [Related]
6. A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.
Watanabe S; Otani T; Iwasa T; Takahama T; Takeda M; Sakai K; Nishio K; Ito A; Nakagawa K
Clin Breast Cancer; 2019 Oct; 19(5):e589-e592. PubMed ID: 31301988
[No Abstract] [Full Text] [Related]
7. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Geyer FC; Li A; Papanastasiou AD; Smith A; Selenica P; Burke KA; Edelweiss M; Wen HC; Piscuoglio S; Schultheis AM; Martelotto LG; Pareja F; Kumar R; Brandes A; Fan D; Basili T; Da Cruz Paula A; Lozada JR; Blecua P; Muenst S; Jungbluth AA; Foschini MP; Wen HY; Brogi E; Palazzo J; Rubin BP; Ng CKY; Norton L; Varga Z; Ellis IO; Rakha EA; Chandarlapaty S; Weigelt B; Reis-Filho JS
Nat Commun; 2018 May; 9(1):1816. PubMed ID: 29739933
[TBL] [Abstract][Full Text] [Related]
8. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
10. Breast adenomyoepithelioma and adenomyoepithelioma with carcinoma (malignant adenomyoepithelioma) with associated breast malignancies: A case series emphasizing histologic, radiologic, and clinical correlation.
Moritz AW; Wiedenhoefer JF; Profit AP; Jagirdar J
Breast; 2016 Oct; 29():132-9. PubMed ID: 27494340
[TBL] [Abstract][Full Text] [Related]
11. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of organoids from a patient with adenomyoepithelioma of the breast.
Luo X; She J; Xu T; Zhou Y; Xu C; Jiang J; Li T; Liu H; Shen H; Yin B; Dai B
Bioengineered; 2021 Dec; 12(2):11578-11585. PubMed ID: 34874791
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
15. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.
Escandell I; Cabezas M; Martín JM; Terradez L; Pinazo MI
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1224-6. PubMed ID: 25917403
[No Abstract] [Full Text] [Related]
17. MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma.
Baraban E; Zhang PJ; Jaffer S; Lubin D; Feldman M; Bleiweiss IJ; Nayak A
Histopathology; 2018 Dec; 73(6):897-903. PubMed ID: 30003572
[TBL] [Abstract][Full Text] [Related]
18. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
19. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
